WellDoc

The company develops mobile solutions to drive behavioral and clinical change in chronic disease. WellDoc’s goal is to improve patient self-management and help physicians overcome gaps in the delivery system to improve clinical outcomes and decrease cost. WellDoc is best known for its flagship product BlueStar, which is a digital therapeutic for adults with type 2 diabetes.

BlueStar

WellDoc validates potential of BlueStar to reduce healthcare costs

The company worked with Truven Health Analytics to show that BlueStar can save on average a range of $254 to $271 per user per month.
BlueStar C app

WellDoc’s diabetes management app BlueStar C coming to Samsung Health

BlueStar C is a diabetes health tool designed to aid individuals living with diabetes in managing their chronic condition.
Bluestar diabetes coaching app

WellDoc, HTAA team-up to address diabetes in trucking industry

WellDoc has also unveiled its consumer diabetes health app, BlueStar C, to aid individuals living with diabetes manage their chronic condition.

Non-prescription version of WellDoc’s BlueStar Digital Therapeutic gets FDA 510(k) clearance

The non-prescription version will have all the first-in-class features of BlueStar® Rx apart from an insulin calculator.
BlueStar app

WellDoc, AADE team-up to enhance the BlueStar Digital Therapeutic Platform

This is the first time AADE has partnered with an organization to provide its curriculum in a consumer-friendly digital format.
Verio Flex

LifeScan, WellDoc team-up to advance mobile care for Type 2 diabetes patients

The two companies will integrate LifeScan's OneTouch Verio Flex blood glucose monitoring system with WellDoc's BlueStar diabetes management platform.
BlueStar app

WellDoc gets $22M Series B for its diabetes management solution

The company will use the funds to accelerate adoption of BlueStar mobile prescription therapy for adults living with type 2 diabetes.
WellDoc BlueStar S

WellDoc, Samsung and OTN launch a pilot for patients with type 2 diabetes

The program will include a minimum of 300 people living with type 2 diabetes who will receive a prescription of BlueStar-S from their healthcare provider.